In his recent report on Alcon, BTIG analyst Ryan Zimmerman estimated that its pharmaceutical portfolio could generate close to $900m in fiscal year 2022.

The market for new company creation in the biopharma sector remains healthy and poised to continue fostering the establishment of start-ups, based on a new In Vivo study of the strong initial investments that pharma and biotech companies receive.

Public Company Edition: Blackstone Life Sciences Yield will finance approved products, while the firm’s prior fund supports late-stage programs. Also, Coeptis will merge with a SPAC, Bausch + Lomb secured post-IPO debt, and BioXcel revealed a $260m financing and new subsidiary.

The French major has entered a risk-sharing collaboration with Blackstone focused on a new formulation of multiple myeloma drug Sarclisa, which could help it take on market leader Darzalex.